Dr. Heather Ellen Marancenbaum, MD

Dr. Marancenbaum practices at Memorial Medical Center in Las Cruces, New Mexico, part of Lifepoint Health.

Dr. Marancenbaum's NPI, 1528073384, was assigned on July 30, 2006. Dr. Marancenbaum holds New Mexico license MD2015-0170.

Dr. Marancenbaum's primary practice is Memorial Medical Center, at 2450 South Telshor Blvd, Las Cruces, NM 88011 in Dona Ana County. The practice phone is (575) 522-8641.

Dr. Marancenbaum's primary practice is Memorial Medical Center in Las Cruces, New Mexico, part of Lifepoint Health. Dr. Marancenbaum is also affiliated with Los Alamos Medical Center. The medical group on file is MountainView Regional Medical Center. Dmand AI also links Dr. Marancenbaum to 2 more hospitals and 6 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Marancenbaum practices, 4 sites in all. Vendor and product names are available with a free account.

Emergency medicine is Dr. Marancenbaum's primary specialty in the NPI Registry, under taxonomy code 207P00000X. Dmand AI has Dr. Marancenbaum's licenses on file in 2 states: New Mexico and Oklahoma.

CMS data shows 308 Medicare services from Dr. Marancenbaum across 5 procedure codes in 2024, for 229 Medicare patients. Medicare paid $28,052 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 229 Medicare patients who saw Dr. Marancenbaum in 2024. The largest group is 75 to 84, with 78 patients. 75% of them have high blood pressure, and 69% have high cholesterol. 29% are also on Medicaid. Their average risk score is 1.80, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Marancenbaum's median patient age at 40, with 54% women.

In 2024, Dr. Marancenbaum wrote 239 Medicare Part D claims for 176 patients. 92% of them were for generic drugs. CMS names the drug for 139 of them, across 7 drugs with 11 or more claims each, at $836 in total drug cost. In 2023, CMS named 141 claims across 7 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 89 out of 100 for Dr. Marancenbaum for performance year 2024, reported as part of a group. Dr. Marancenbaum accepts Medicare assignment, so Medicare's approved amount is taken as full payment.

CMS Open Payments shows 1 general payment to Dr. Marancenbaum from 1 drug or device company in 2022. Food and beverage make up the largest share, 100% of the total. AstraZeneca Pharmaceuticals LP paid the most, $90.